AR053913A1 - Cepa atenuada de dengue serotipo 1 - Google Patents

Cepa atenuada de dengue serotipo 1

Info

Publication number
AR053913A1
AR053913A1 ARP060102566A ARP060102566A AR053913A1 AR 053913 A1 AR053913 A1 AR 053913A1 AR P060102566 A ARP060102566 A AR P060102566A AR P060102566 A ARP060102566 A AR P060102566A AR 053913 A1 AR053913 A1 AR 053913A1
Authority
AR
Argentina
Prior art keywords
strain
dengue serotype
dengue
damaged strain
vdv1
Prior art date
Application number
ARP060102566A
Other languages
English (en)
Inventor
Richard M Kinney
Claire Y Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Ct S For Desease Control And P
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct S For Desease Control And P, Sanofi Pasteur filed Critical Ct S For Desease Control And P
Publication of AR053913A1 publication Critical patent/AR053913A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invencion se refiere a cepas de VDV1 (virus dengue serotipo 1 derivado de Vero) atenuadas vivas, que derivan de la cepa de dengue-1 de tipo silvestre 16007 por pasaje en células PDK y sanitizacion en células Vero. La invencion también se refiere a una composicion de vacuna que comprende una cepa de VDV1.
ARP060102566A 2005-06-17 2006-06-16 Cepa atenuada de dengue serotipo 1 AR053913A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US69124305P 2005-06-17 2005-06-17

Publications (1)

Publication Number Publication Date
AR053913A1 true AR053913A1 (es) 2007-05-23

Family

ID=36933493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060102566A AR053913A1 (es) 2005-06-17 2006-06-16 Cepa atenuada de dengue serotipo 1

Country Status (16)

Country Link
US (3) US7641907B2 (es)
EP (1) EP1893637B1 (es)
JP (1) JP5197362B2 (es)
KR (2) KR101536612B1 (es)
CN (1) CN101238144B (es)
AR (1) AR053913A1 (es)
AU (1) AU2006257610B2 (es)
BR (1) BRPI0613328A2 (es)
CA (1) CA2611934C (es)
IL (1) IL188041A0 (es)
MX (1) MX2007015873A (es)
MY (1) MY144689A (es)
NO (1) NO20076355L (es)
TW (1) TWI414605B (es)
WO (1) WO2006134433A1 (es)
ZA (1) ZA200710714B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122018075730B1 (pt) 2002-01-15 2022-04-19 Acambis, Inc Flavivírus na preparação de uma composição de vacina e composição de vacina
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
JP6057460B2 (ja) 2009-08-31 2017-01-11 ジェン−プローブ・インコーポレーテッド デングウイルスアッセイ
CN104812408A (zh) * 2012-07-24 2015-07-29 赛诺菲巴斯德有限公司 用于防止登革热病毒感染的疫苗组合物
SG11201500412TA (en) * 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
EP2931310A4 (en) * 2012-12-14 2016-05-25 Takeda Vaccines Inc COMPOSITIONS, METHODS OF ADMINISTRATION AND USES OF TRIVALENT FORMULATIONS AGAINST DENGUE VIRUS
CA3166063A1 (en) * 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
US9861692B2 (en) 2013-06-21 2018-01-09 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
CN106999564A (zh) 2014-09-02 2017-08-01 赛诺菲巴斯德有限公司 针对登革热病毒疾病的疫苗组合物
MX2017008342A (es) 2014-12-22 2017-10-24 Merck Sharp & Dohme Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
US10857222B2 (en) 2015-07-03 2020-12-08 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017090762A1 (ja) * 2015-11-27 2017-06-01 一般財団法人化学及血清療法研究所 デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
CN1191092C (zh) * 1999-03-26 2005-03-02 沃尔特里德军事研究院 多价登革病毒疫苗
AU3844101A (en) * 2000-02-16 2001-08-27 Us Health Avirulent, immunogenic flavivirus chimeras
ES2315221T3 (es) * 2000-05-30 2009-04-01 Mahidol University Cepas atenuadas del virus del dengue y su utilizacion en una composicion vaccinea.
AU2356002A (en) 2000-09-25 2002-04-02 Polymun Scient Immunbio Forsch Live vaccine and method of manufacture
CA3114957C (en) 2001-05-22 2022-02-08 Stephen S. Whitehead Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
EP3763382A1 (en) * 2002-05-03 2021-01-13 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4
JP4537045B2 (ja) * 2003-12-11 2010-09-01 キヤノン株式会社 電子ペーパー、電子ペーパー接続装置、システム、電子ペーパーにおける制御方法及びコンピュータプログラム

Also Published As

Publication number Publication date
TW200741002A (en) 2007-11-01
KR101464649B1 (ko) 2014-12-01
US20100137571A1 (en) 2010-06-03
KR20080027356A (ko) 2008-03-26
TWI414605B (zh) 2013-11-11
US9169298B2 (en) 2015-10-27
IL188041A0 (en) 2008-03-20
ZA200710714B (en) 2008-11-26
KR101536612B1 (ko) 2015-07-14
WO2006134433A1 (en) 2006-12-21
AU2006257610A1 (en) 2006-12-21
CN101238144B (zh) 2012-09-05
MX2007015873A (es) 2008-04-22
MY144689A (en) 2011-10-31
CA2611934A1 (en) 2006-12-21
NO20076355L (no) 2008-03-11
CN101238144A (zh) 2008-08-06
KR20140006119A (ko) 2014-01-15
AU2006257610B2 (en) 2012-11-15
EP1893637A1 (en) 2008-03-05
US7641907B2 (en) 2010-01-05
EP1893637B1 (en) 2016-01-06
BRPI0613328A2 (pt) 2011-01-04
CA2611934C (en) 2015-11-03
US20120083584A1 (en) 2012-04-05
US8067565B2 (en) 2011-11-29
JP5197362B2 (ja) 2013-05-15
JP2008546382A (ja) 2008-12-25
US20060292172A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
AR053913A1 (es) Cepa atenuada de dengue serotipo 1
AR053914A1 (es) Cepa atenuada del dengue serotipo 2
EA200870304A1 (ru) Псевдоинфекционный флавивирус и его применение
PH12015500773A1 (en) Methods and compositions for live attenuated viruses
BRPI0913012A2 (pt) vírus do nilo ocidental/da dengue quiméricos
CL2011000502A1 (es) Composicion que comprende al menos una bacteria formadora de esporas, al menos un agente para combatir insectos y un disolvente; y procedimiento proteger una semilla, parte vegetal o planta geneticamente modificada de nematodos basado en la aplicacion de la composicion descrita anteriormente.
CR9076A (es) Metodo y materiales para conferir resistencia a las pestes y patogenos de plantas
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
BRPI0908489A2 (pt) uso de compostos químicos e método para desenhar compostos químicos que atenuam ou inibem a infecção pelo vírus da dengue
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
SG170751A1 (en) Extractions and methods comprising elder species
EA201390538A1 (ru) Противовирусные соединения
EA201591888A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
TW200732476A (en) Functional influenza virus like particles (VLPs)
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
MY163972A (en) Attenuated recombinant newcastle disease virus and vaccine containing the same
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
ES2585242T3 (es) Cepas virales obtenidas del virus vaccinia Lister VACV-107 y usos de las mismas
CO6400154A2 (es) Una planta con inflorescencia alterada
AR061197A1 (es) Cepas del virus 3 del dengue vivas atenuadas
WO2010008576A3 (en) Idna vaccines and methods for using the same
CO6410260A2 (es) Una composición de repelente botánico a base de allium sativum y ácidos húmicos para combatir insectos plaga y procedimiento de obtención y usos
AR124384A1 (es) Parapoxvirus modificado que tiene inmunogenicidad aumentada

Legal Events

Date Code Title Description
FB Suspension of granting procedure